2-氯-4-甲氧基嘧啶-5-甲腈 | 1106295-93-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-氯-4-甲氧基嘧啶-5-甲腈
• 中文别名: 2-氯-4-甲氧基-嘧啶-5-甲腈
• 英文名称: 2-chloro-4-methoxypyrimidine-5-carbonitrile
• CAS: 1106295-93-5
• 化学式: C₆H₄ClN₃O
• 分子量: 169.57
• InChiKey: YIGFAXAWUVBGGI-UHFFFAOYSA-N

物化性质

• 沸点：
  385.1±22.0 °C(Predicted)
• 密度：
  1.41±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  58.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Chloro-4-methoxypyrimidine-5-carbonitrile
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloro-4-methoxypyrimidine-5-carbonitrile
CAS number: 1106295-93-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H4ClN3O
Molecular weight: 169.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-4-甲氧基嘧啶-5-甲腈 在 三甲基氯硅烷 、 N,N-二异丙基乙胺 、 sodium iodide 作用下， 以 二甲基亚砜 、 乙腈 为溶剂， 反应 4.0h， 生成 2-{[(1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino}-4-hydroxypyrimidine-5-carbonitrile
  参考文献：
  名称：

  QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS

  摘要：

  这项发明涉及对突变异构异柠檬酸脱氢酶（mt-IDH）蛋白的抑制剂，具有新陈代谢活性，可用于治疗细胞增殖紊乱和癌症，其化学式为：其中A、B、W1、W2、W3和R1-R6如本文所述。

  公开号：

  US20160083365A1
• 作为产物：
  描述：

  2-chloro-4-methoxy-5-N-tert-butyl-aminoformylpyrimidine 在 sulfoxide 作用下， 反应 4.0h， 以71%的产率得到2-氯-4-甲氧基嘧啶-5-甲腈
  参考文献：
  名称：

  一种2-氯-4-甲氧基-5-氰基嘧啶的合成方法

  摘要：

  本发明公开了一种2‑氯‑4‑甲氧基‑5‑氰基嘧啶的合成方法，通过2，4‑二氯‑5‑嘧啶甲酰氯、叔丁胺和有机碱反应制得2,4‑二氯‑5‑嘧啶叔丁酰胺，2,4‑二氯‑5‑嘧啶叔丁酰胺和无水甲醇、20%甲醇钠甲醇溶液反应制得2‑氯‑4‑甲氧基‑5‑嘧啶叔丁酰胺，2‑氯‑4‑甲氧基‑5‑嘧啶叔丁酰胺和氯化亚砜反应后，依次通过乙酸乙酯萃取，饱和碳酸氢钠水溶液、饱和食盐水吸收反应中产生的二氧化硫和氯化氢气体等有害气体，无水硫酸钠对产物进行干燥，正己烷进行重结晶制得2‑氯‑4‑甲氧基‑5‑氰基嘧啶，与现有技术相比，该发明不仅生产出一种新的医药中间体，并与现有技术已知的方法相比收率和纯度高，污染小，工艺反应流程短。

  公开号：

  CN110452179A

文献信息

• Boron-Containing Small Molecules as Anti-Inflammatory Agents
  申请人：ANACOR PHARMACEUTICALS, INC.

  公开号：US20150291629A1

  公开（公告）日：2015-10-15

  Compounds and methods of treating anti-inflammatory conditions are disclosed.

  化合物和治疗抗炎症状况的方法被披露。
• [EN] SUBSTITUTED NITROGEN CONTAINING COMPOUNDS<br/>[FR] COMPOSÉS CONTENANT DE L'AZOTE SUBSTITUÉ
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018222795A1

  公开（公告）日：2018-12-06

  Disclosed are compounds of Formula (I): or a salt thereof, Formula (II) wherein R1 is: or; each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

  揭示了以下式（I）的化合物或其盐，式（II）其中R1是：或；每个W独立地是NR1b或O；Z是键或CHR1d；以及R1、R2、Rd、R3a、R3b、L1、B、V、Y和n在此处被定义。还揭示了将这些化合物用作ROMK抑制剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗心血管疾病方面是有用的。
• Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors
  作者：Jian Lin、Wei Lu、Justin A. Caravella、Ann Marie Campbell、R. Bruce Diebold、Anna Ericsson、Edward Fritzen、Gary R. Gustafson、David R. Lancia、Tatiana Shelekhin、Zhongguo Wang、Jennifer Castro、Andrea Clarke、Deepali Gotur、Helen R. Josephine、Marie Katz、Hien Diep、Mark Kershaw、Lili Yao、Goss Kauffman、Stephen E. Hubbs、George P. Luke、Angela V. Toms、Liann Wang、Kenneth W. Bair、Kenneth J. Barr、Christopher Dinsmore、Duncan Walker、Susan Ashwell

  DOI：10.1021/acs.jmedchem.9b00362

  日期：2019.7.25

  cancers. Inhibition of mutant IDH1 (mIDH1) with small molecules has been clinically validated as a promising therapeutic treatment for acute myeloid leukemia and multiple solid tumors. Herein, we report the discovery and optimization of a series of quinolinones to provide potent and orally bioavailable mIDH1 inhibitors with selectivity over wild-type IDH1. The X-ray structure of an early lead 24 in complex

  在各种人类癌症中经常发现异柠檬酸脱氢酶1（IDH1）中精氨酸残基（R132）的突变。小分子抑制突变IDH1（mIDH1）已被临床验证为急性髓细胞性白血病和多发实体瘤的有前途的治疗方法。在此，我们报告了一系列喹啉酮的发现和优化，以提供对野生型IDH1具有选择性的有效和口服生物利用性mIDH1抑制剂。与mIDH1-R132H结合的早期铅24的X射线结构表明，该抑制剂出乎意料地结合了变构位点。努力改善24的体外和体内吸收，分布，代谢和排泄（ADME）特性，产生了临床前候选药物63。
• BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS
  申请人：Akama Tsutomu

  公开号：US20120214765A1

  公开（公告）日：2012-08-23

  Compounds and methods of treating anti-inflammatory conditions are disclosed.

  本发明公开了治疗抗炎症状况的化合物和方法。
• Boron-containing small molecules as anti-inflammatory agents
  申请人：Anacor Pharmaceuticals, Inc.

  公开号：EP2564857A1

  公开（公告）日：2013-03-06

  Compounds and methods of treating anti-inflammatory conditions are disclosed. The compounds are benzoxaboroles and in particular are 5-phenoxy-1-hydroxy-2,1-benzoxaboroles and 5-pyridin-2-yloxy-1-hydroxy-2,1-benzoxaboroles.

  本发明公开了治疗抗炎症状的化合物和方法。这些化合物是苯并氧硼烷，特别是 5-苯氧基-1-羟基-2,1-苯并氧硼烷和 5-吡啶-2-基氧基-1-羟基-2,1-苯并氧硼烷。